Evidence map›Paper›PMID 40862151›Full record

ArticleFrontiers in microbiology2025

Epidemiological and clinical impact of hepatitis E virus coinfection in chronic hepatitis B infected patients in Hebei, China.

Yuzhu Shi, Yuchen Xie, Ying Chen, Li Yang, Huixia Gao, Yun Guo, Fumin Feng, Jianhua Lu, Erhei Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuzhu Shi *School of Public Health, North China University of Science and Technology, Tangshan, China.
Yuchen Xie *School of Public Health, North China University of Science and Technology, Tangshan, China.
Ying Chen *Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, Hebei, China.
Li YangHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, Hebei, China.
Huixia GaoHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, Hebei, China.
Yun GuoHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, Hebei, China.
Fumin FengSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Jianhua LuHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, Hebei, China.
Erhei DaiHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatitis B virus (HBV) infection poses a major global public health challenge. Recent studies have highlighted the clinical implications of coinfection with the hepatitis E virus (HEV) in HBV-infected individuals, as this dual infection is associated with exacerbated disease severity. However, epidemiological data on HBV/HEV coinfection in the Hebei region are scarce, necessitating further investigation. Methods: We conducted a multicenter cross-sectional study for infectious diseases across six tertiary hospitals. Serum samples were screened for anti-HEV IgM and IgG antibodies by using an automated chemiluminescent immunoassay. Samples positive for anti-HEV antibodies were further subjected to HEV RNA detection using the reverse transcription polymerase chain reaction (RT-PCR). The seroprevalence of anti-HEV antibodies was 18.70% (582/3,113). Results: Among these, 562 cases were positive for anti-HEV IgG, 4 were positive for anti-HEV IgM, and 16 were positive for both anti-HEV IgG and IgM. HEV RNA was detected in 16 (2.75%; 582) anti-HEV-seropositive individuals. A strong positive correlation was observed between anti-HEV seroprevalence and advancing age [ Discussion: Our findings demonstrated an 18.70% seroprevalence of anti-HEV antibodies among chronically HBV-infected patients in the Hebei Province, with a significantly higher risk of coinfection in older individuals. HBV/HEV coinfection may aggravate liver injury and impair coagulation. These results provide valuable insights into the epidemiology and clinical consequences of HBV/HEV coinfection in this region.

Indexed as

coinfectionepidemiologyhepatitis B virushepatitis E virusliver injury

Identifiers

PMID40862151
PMCPMC12375558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.